Full Track-and-Trace Anti-Counterfeiting Not Feasible, Industry Tells FDA
This article was originally published in The Gold Sheet
Executive SummaryThe U.S. pharmaceutical industry is telling FDA that a full track-and-trace approach for following drugs through the supply chain is not the best way of dealing with the growing counterfeit problem. In the meantime, industry is devising a number of different approaches.
You may also be interested in...
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.